Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress ...Middle East

SHANGHAI, Oct. 12, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, has unveiled its phase III...

Hence then, the article about asieris unveiled results of its phase iii clinical study for apl 1706 an imaging drug for diagnosis or surgery of bladder cancer at the siu 2023 congress was published today ( Thursday 12/10/2023 - 01:52 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress )

Also on site :

• Biden Loyalist: Platner’s Nazi Tat, Wife-Beating, Pedo App & Rape Fantasies Aren’t Just ‘Transgressions’
• Trump celebrates 80th birthday with a UFC fight at the White House as Americans pay the price for his Iran war
• Republican attorneys general urge EPA to classify mifepristone as water contaminant